Mesenteric benign lymph node enlargement in colorectal cancer: Friend or foe?
Introduction: Benign lymph node enlargement (BLNE) is common in colorectal cancer; however, few studies have investigated its influence on prognosis, clinicopathological features, and pathogenesis. Methods: A cohort study was conducted to analyze the clinicopathologic features and prognosis of color...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523325000993 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850188167345340416 |
|---|---|
| author | Wang Junwei Chen Xin Guo Limei Li Fei Lu Siyi Ma Yao Hsinyi Lin Shi Xiangchao Fu Wei Zhou Xin |
| author_facet | Wang Junwei Chen Xin Guo Limei Li Fei Lu Siyi Ma Yao Hsinyi Lin Shi Xiangchao Fu Wei Zhou Xin |
| author_sort | Wang Junwei |
| collection | DOAJ |
| description | Introduction: Benign lymph node enlargement (BLNE) is common in colorectal cancer; however, few studies have investigated its influence on prognosis, clinicopathological features, and pathogenesis. Methods: A cohort study was conducted to analyze the clinicopathologic features and prognosis of colorectal cancer patients, categorized based on the presence or absence of BLNE. Given the correlation between lymph nodes and immune response, immunohistochemistry, transcriptome analysis, and exon sequencing were employed to further investigate the differences in the immune microenvironment of primary tumors. Results: Overall, 630 AJCC stage I/II patients were included in the study, with 131 in the BLNE group and 499 in the Non-BLNE (NBLNE) group. Patients in the BLNE group were found to have a significantly better disease-free survival (DFS) (hazard ratio [HR] 0.44, P = 0.016) and overall survival (OS) (HR 0.46, P = 0.011) than those in the NBLNE group. Pathologically, compared with the NBLNE group, the BLNE group had more mature tertiary lymphoid structures (66.7 % vs. 36.5 %, P = 0.002) and higher immunoscores (18.8 % vs. 2.1 %, P = 0.004) in primary tumor tissue. Also, transcriptome analysis showed that, compared with NBLNE, the genes upregulated in BLNE were enriched in immune-related pathways, such as adaptive immune response and immuno-regulatory interactions. Whole-exon sequencing analysis revealed a higher tumor mutation burden (TMB) in the BLNE group [6.03 (5.59, 7.59) vs. 5.33 (4.62, 6.34), P = 0.025]. Conclusion: BLNE is positively associated with the prognosis of colorectal cancer, possibly because patients with BLNE have a stronger anti-tumor immune response. |
| format | Article |
| id | doaj-art-292d57a308dc4e849e8ea122b1e725b9 |
| institution | OA Journals |
| issn | 1936-5233 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj-art-292d57a308dc4e849e8ea122b1e725b92025-08-20T02:15:58ZengElsevierTranslational Oncology1936-52332025-06-015610236810.1016/j.tranon.2025.102368Mesenteric benign lymph node enlargement in colorectal cancer: Friend or foe?Wang Junwei0Chen Xin1Guo Limei2Li Fei3Lu Siyi4Ma Yao5Hsinyi Lin6Shi Xiangchao7Fu Wei8Zhou Xin9Department of General Surgery, Peking University Third Hospital, PR China; Peking university third hospital cancer center, PR China; Beijing Key Laboratory of Collaborative Innovation in Gastrointestinal Oncology, PR ChinaDepartment of General Surgery, Peking University Third Hospital, PR China; Peking university third hospital cancer center, PR ChinaDepartment of Pathology, School of Basic Medical Sciences, Peking University Third Hospital, PR ChinaDepartment of General Surgery, Peking University Third Hospital, PR China; Peking university third hospital cancer center, PR ChinaDepartment of General Surgery, Peking University Third Hospital, PR China; Peking university third hospital cancer center, PR ChinaDepartment of General Surgery, Peking University Third Hospital, PR China; Peking university third hospital cancer center, PR ChinaDepartment of General Surgery, Peking University Third Hospital, PR China; Peking university third hospital cancer center, PR ChinaDepartment of General Surgery, Peking University Third Hospital, PR China; Peking university third hospital cancer center, PR China; Corresponding authors at: Department of General Surgery, Peking University Third Hospital, PR China.Department of General Surgery, Peking University Third Hospital, PR China; Peking university third hospital cancer center, PR China; Corresponding authors at: Department of General Surgery, Peking University Third Hospital, PR China.Department of General Surgery, Peking University Third Hospital, PR China; Peking university third hospital cancer center, PR China; Beijing Key Laboratory of Collaborative Innovation in Gastrointestinal Oncology, PR China; Corresponding authors at: Department of General Surgery, Peking University Third Hospital, PR China.Introduction: Benign lymph node enlargement (BLNE) is common in colorectal cancer; however, few studies have investigated its influence on prognosis, clinicopathological features, and pathogenesis. Methods: A cohort study was conducted to analyze the clinicopathologic features and prognosis of colorectal cancer patients, categorized based on the presence or absence of BLNE. Given the correlation between lymph nodes and immune response, immunohistochemistry, transcriptome analysis, and exon sequencing were employed to further investigate the differences in the immune microenvironment of primary tumors. Results: Overall, 630 AJCC stage I/II patients were included in the study, with 131 in the BLNE group and 499 in the Non-BLNE (NBLNE) group. Patients in the BLNE group were found to have a significantly better disease-free survival (DFS) (hazard ratio [HR] 0.44, P = 0.016) and overall survival (OS) (HR 0.46, P = 0.011) than those in the NBLNE group. Pathologically, compared with the NBLNE group, the BLNE group had more mature tertiary lymphoid structures (66.7 % vs. 36.5 %, P = 0.002) and higher immunoscores (18.8 % vs. 2.1 %, P = 0.004) in primary tumor tissue. Also, transcriptome analysis showed that, compared with NBLNE, the genes upregulated in BLNE were enriched in immune-related pathways, such as adaptive immune response and immuno-regulatory interactions. Whole-exon sequencing analysis revealed a higher tumor mutation burden (TMB) in the BLNE group [6.03 (5.59, 7.59) vs. 5.33 (4.62, 6.34), P = 0.025]. Conclusion: BLNE is positively associated with the prognosis of colorectal cancer, possibly because patients with BLNE have a stronger anti-tumor immune response.http://www.sciencedirect.com/science/article/pii/S1936523325000993Colorectal cancerPrognosisTumor immune microenvironmentBenign lymph node enlargement |
| spellingShingle | Wang Junwei Chen Xin Guo Limei Li Fei Lu Siyi Ma Yao Hsinyi Lin Shi Xiangchao Fu Wei Zhou Xin Mesenteric benign lymph node enlargement in colorectal cancer: Friend or foe? Translational Oncology Colorectal cancer Prognosis Tumor immune microenvironment Benign lymph node enlargement |
| title | Mesenteric benign lymph node enlargement in colorectal cancer: Friend or foe? |
| title_full | Mesenteric benign lymph node enlargement in colorectal cancer: Friend or foe? |
| title_fullStr | Mesenteric benign lymph node enlargement in colorectal cancer: Friend or foe? |
| title_full_unstemmed | Mesenteric benign lymph node enlargement in colorectal cancer: Friend or foe? |
| title_short | Mesenteric benign lymph node enlargement in colorectal cancer: Friend or foe? |
| title_sort | mesenteric benign lymph node enlargement in colorectal cancer friend or foe |
| topic | Colorectal cancer Prognosis Tumor immune microenvironment Benign lymph node enlargement |
| url | http://www.sciencedirect.com/science/article/pii/S1936523325000993 |
| work_keys_str_mv | AT wangjunwei mesentericbenignlymphnodeenlargementincolorectalcancerfriendorfoe AT chenxin mesentericbenignlymphnodeenlargementincolorectalcancerfriendorfoe AT guolimei mesentericbenignlymphnodeenlargementincolorectalcancerfriendorfoe AT lifei mesentericbenignlymphnodeenlargementincolorectalcancerfriendorfoe AT lusiyi mesentericbenignlymphnodeenlargementincolorectalcancerfriendorfoe AT mayao mesentericbenignlymphnodeenlargementincolorectalcancerfriendorfoe AT hsinyilin mesentericbenignlymphnodeenlargementincolorectalcancerfriendorfoe AT shixiangchao mesentericbenignlymphnodeenlargementincolorectalcancerfriendorfoe AT fuwei mesentericbenignlymphnodeenlargementincolorectalcancerfriendorfoe AT zhouxin mesentericbenignlymphnodeenlargementincolorectalcancerfriendorfoe |